You should stop taking antibiotics once your symptoms have subsided. The drugs may not be able to kill all bacteria. You will soon develop another infection. Only this time, stronger antibiotics are required to stop it.
Non-compliance by patients, i.e. taking antibiotics incorrectly, is the main reason why antibiotics fail. Misusing antibiotics can lead to resistant bacteria.
Even patients who have good intentions can fall apart. According to a 2009 study done by Spain’s University Rovira i Virgili in Spain, 55.1 percent of patients who took antibiotics three times daily failed to finish at least 80 per cent of their medication. This is mainly because they forgot their afternoon dose. The study found that patients who were given antibiotics daily had an 86.7 percent higher compliance rate.
For your own safety, consult your doctor about the once-a day dosages. The FDA approved Moxatag, a once-a-day antibiotic to treat strep throat, as opposed to the usual twice-daily or three-time-daily regimens. Moxatag is a combination of a “pulse”Delivery system — The tablet slowly releases amoxicillin as it passes through the digestive tract. This technology allows for the antibiotic to be effective in killing strep throat bacteria by only requiring a once-daily dose. Other penicillin family regimens require several daily doses.
Antibiotic resistance can be avoided by making sure you have the right antibiotics. A test for strep throat is the only way to diagnose it. If your test results are negative, you do not need antibiotics. Your doctor should not recommend you ask for stronger drugs or newer ones. The best treatment for strep is penicillin-class antibiotics like amoxicillin. There are no cases of resistance. Strep can, however, resist stronger antibiotics.
Visit this site for more information www.moxatag.com.
Important Safety Information
MOXATAG should not be used in patients with a history of severe hypersensitivity to amoxicillin, other drugs from the same class, and patients who have had anaphylactic reactions. Patients receiving penicillin therapy have experienced severe and sometimes fatal hypersensitivity reactions (anaphylactic) reactions. MOXATAG should be stopped immediately if there is an allergic reaction and the appropriate therapy should be started. Clostridium difficile associated diarrhea (CDAD), which has been reported with almost all antibacterial agents including amoxicillin, can range in severity from mild diarrhea and fatal colitis. MOXATAG should immediately be stopped if CDAD is confirmed. While on therapy, it is important to consider the possibility of superinfections by mycotic or other bacterial pathogens. Superinfections should be treated immediately and MOXATAG should not be used again. Clinical studies have shown that MOXATAG is associated with the most drug-related adverse reactions, including diarrhea (2.3%), nausea (1.3%) and vomiting (0.7%).
MOXATAG has been approved for patients aged 12 and older. MOXATAG, a registered trademark of MiddleBrook Pharmaceuticals, Inc. www.moxatag.comFor additional safety information about Moxatag, click here. MiddleBrook Pharmaceuticals, Inc. sponsored this article
